The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
Andre Poisl Fay
No relevant relationships to disclose
Marcella Callea
No relevant relationships to disclose
Kathryn P. Gray
No relevant relationships to disclose
Thai Huu Ho
No relevant relationships to disclose
Jiaxi Song
No relevant relationships to disclose
Ingrid Carvo
No relevant relationships to disclose
Megan E. Lampron
No relevant relationships to disclose
Laurence Albiges
Consultant or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Honoraria - Novartis; Pfizer
Research Funding - Novartis; Pfizer
Melissa L. Stanton
No relevant relationships to disclose
David F. McDermott
No relevant relationships to disclose
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb; Merck; Prometheus
Gordon James Freeman
Stock Ownership - Amplimmune; Boehringer-Mannheim; Bristol-Myers Squibb; CoStim; EMD Serono; Merck; Roche/Genentech
Research Funding - CoStim
Michelle S. Hirsch
No relevant relationships to disclose
Sabina Signoretti
No relevant relationships to disclose
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer